Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zentalis · 1 trial · 3 indications
6-month PFS rate is the proportion of participants remaining alive and progression free at 6 months. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.
| Arm | Type | Description |
|---|---|---|
| ZN-c3 + Gemcitabine | EXPERIMENTAL | Study procedures will be conducted as follows: * Cycle 1 - End of Treatment * Days 1 - 5 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Days 8 - 12 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Days 15 - 19 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Day 1 and 8 of 21-day cycle: Predetermined dose of Gemcitabine 1x daily. * On-treatment tumor biopsy will be collected on either Cycle 1 Day 9 - 10 or Cycle 2 Day 9 - 10. * Tumor assessment by Computerized Tomography (CT) or Magnetic Resonance Imaging scan every 8 weeks while on treatment. * End of treatment visit with tumor assessment by CT or MRI and optional tumor biopsy. * Follow up visit every 2 months after treatment has ended. |
| Name | Type | Description |
|---|---|---|
| Zentalis | DRUG | Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol. |
| Gemzar | DRUG | Nucleoside metabolic inhibitor, per standard care via intravenous infusion. |
Inclusion Criteria: * Participants must have a pathologically confirmed advanced pancreatic adenocarcinoma that is not curable with standard approaches based on the judgement of the treating investigator. Patients with metastatic pancreatic cancer and unresectable pancreatic cancer are eligible. * ...
Zentalis is an investigational small molecule being studied for the treatment of advanced pancreatic adenocarcinoma, including pancreatic ductal adenocarcinoma. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The molecular target of Zentalis has not been disclosed in the available information. It is a small molecule being evaluated in combination with gemcitabine for advanced pancreatic cancer, but its specific mechanism of action is not specified.
Zentalis is being developed by Zentalis Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZNTL. The company is conducting clinical trials to evaluate the drug's safety and efficacy in pancreatic cancer.
Zentalis is in Phase 2 clinical development. It is being studied in an active, non-recruiting clinical trial for advanced pancreatic adenocarcinoma. The drug is investigational and has not yet received FDA approval.
Zentalis is being evaluated in a Phase 2 clinical trial with the identifier NCT06015659, titled 'ZN-c3 + Gemcitabine in Pancreatic Cancer.' This single-arm, open-label study is enrolling 12 participants in the United States and is currently active but not recruiting.
Yes, Zentalis is also known as ZN-c3, as indicated by the clinical trial title 'ZN-c3 + Gemcitabine in Pancreatic Cancer.' The drug is being tested under this alternative name in combination with gemcitabine for advanced pancreatic cancer.